Republican Attorneys General Urge Reinstatement of Mifepristone Safety Regulations

Over 20 Republican Attorneys General are urging the Trump administration to reinstate safety measures concerning Mifepristone, the first drug in a two-drug regimen for abortions.

Led by Chris Kobach, the Attorney General from Kansas, the group wrote to Robert F. Kennedy Jr., the Director of the Department of Health and Human Services (HHS), along with the Food and Drug Administration (FDA). They highlighted the removal of “critical safeguards” that were previously in place during the Obama administration.

Recent studies indicate that serious adverse effects from Mifepristone occur 22 times more often than what is stated on its labeling. This raises doubts about claims of its safety and effectiveness. The Ethics and Public Policy Center (EPPC) emphasized this inconsistency in a recent publication.

According to EPPC research, approximately 10.93% of women who underwent abortions using Mifepristone experienced severe complications, such as sepsis and bleeding, within 45 days post-abortion. This figure starkly contrasts with the less than 0.5% reported in clinical trials reflected on FDA-approved labels.

Ryan T. Anderson, president of the EPPC, termed this research the “most extensive study of abortion drugs to date,” relying on data from more than 865,000 physician-prescribed Mifepristone abortions from 2017 to 2023.

The study argues that the deregulation of abortion drugs has accelerated since their approval in 2000, pointing out that the process then classified pregnancy as an illness needing treatment under a severe framework during the Clinton era.

The initial label for Mifeprex (Mifepristone) from September 2000 stipulated its use within seven weeks of pregnancy and included several safety measures to protect women’s health. These measures consisted of:

• Three required office visits for patients
• Prescriptions issued only by doctors familiar with the medication
• Administration of the drug in a clinical setting with appropriate supervision for conditions like ectopic pregnancies
• Access to medical professionals for possible surgical interventions in cases of complications
• Availability of medical facilities equipped for emergencies like blood transfusions

However, these precautions have been absent from drug approvals for over two decades.

Since the Obama and Biden administrations, current guidelines allow women to receive Mifepristone after just one telehealth consultation with an approved healthcare provider. The FDA has also stopped requiring prescribers to report serious adverse events, other than deaths, since 2016.

Both Robert F. Kennedy Jr. and FDA Commissioner Marty Makary have expressed their commitment to reviewing the safety of abortion drugs following the findings from the EPPC study.

In their letter, the Attorneys General emphasized that the FDA should reassess Mifepristone’s labeling and potentially reinstate safety protocols that had been deemed necessary in 2011 but later removed.

They mentioned that if the FDA cannot revive these protocols, it might be worth considering withdrawing Mifepristone entirely from the market.

The AGs argued that the clinical trials relied upon for the 2016 label changes overlooked many essential safety protections. They also questioned whether the lifts of these safety protocols were prompted by reasons other than patient safety.

Mississippi Attorney General Lynn Fitch expressed concern over the risks posed to women taking this medication without adequate safeguards, emphasizing the need for proper medical supervision.

It’s important to understand that Mifepristone, combined with Misoprostol, blocks progesterone to terminate pregnancies. Generally, the latter causes contractions to expel the uterine content. While side effects like cramps and bleeding are expected, serious complications can occur.

In 2023, medication abortions constituted 63% of all abortions within the formal U.S. healthcare system, indicating a significant rise from previous years, according to the Guttmacher Institute.

Earlier this year, several Republican-led states, including Idaho, Missouri, and Kansas, pressed lawsuits against the FDA’s decision to deregulate Mifepristone.